Saturna Capital Corp Has $28.93 Million Stake in Kenvue Inc. $KVUE

Saturna Capital Corp decreased its position in Kenvue Inc. (NYSE:KVUE) by 2.4% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,676,887 shares of the company’s stock after selling 41,820 shares during the quarter. Saturna Capital Corp’s holdings in Kenvue were worth $28,926,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in KVUE. Elyxium Wealth LLC acquired a new stake in Kenvue in the fourth quarter valued at approximately $26,000. Physician Wealth Advisors Inc. increased its stake in shares of Kenvue by 67.5% during the 4th quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock worth $26,000 after purchasing an additional 618 shares during the last quarter. SBI Securities Co. Ltd. increased its stake in shares of Kenvue by 82.4% during the 4th quarter. SBI Securities Co. Ltd. now owns 2,273 shares of the company’s stock worth $39,000 after purchasing an additional 1,027 shares during the last quarter. Leonteq Securities AG bought a new position in shares of Kenvue during the 4th quarter valued at $45,000. Finally, Hantz Financial Services Inc. raised its holdings in shares of Kenvue by 157.2% during the 3rd quarter. Hantz Financial Services Inc. now owns 2,850 shares of the company’s stock valued at $46,000 after purchasing an additional 1,742 shares in the last quarter. Institutional investors own 97.64% of the company’s stock.

Insider Buying and Selling

In other Kenvue news, General Counsel Matthew Orlando sold 38,491 shares of Kenvue stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $17.66, for a total transaction of $679,751.06. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 1.59% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

KVUE has been the subject of a number of recent research reports. Citigroup decreased their price objective on shares of Kenvue from $20.00 to $19.00 and set a “neutral” rating for the company in a report on Wednesday, April 15th. Canaccord Genuity Group increased their price objective on Kenvue from $17.00 to $18.00 and gave the company a “hold” rating in a report on Wednesday, February 18th. Zacks Research raised Kenvue from a “hold” rating to a “strong-buy” rating in a research note on Friday, May 8th. UBS Group reduced their target price on Kenvue from $19.00 to $18.00 and set a “neutral” rating for the company in a report on Tuesday, April 7th. Finally, Barclays decreased their target price on Kenvue from $19.00 to $18.00 and set an “equal weight” rating for the company in a research report on Tuesday, April 14th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and twelve have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $19.33.

Kenvue Stock Performance

KVUE opened at $18.06 on Thursday. The stock’s 50 day simple moving average is $17.40 and its 200-day simple moving average is $17.52. The company has a current ratio of 0.98, a quick ratio of 0.70 and a debt-to-equity ratio of 0.67. The stock has a market cap of $34.67 billion, a PE ratio of 21.24, a P/E/G ratio of 1.36 and a beta of 0.54. Kenvue Inc. has a 1 year low of $14.02 and a 1 year high of $22.87.

Kenvue (NYSE:KVUE) last issued its earnings results on Thursday, May 7th. The company reported $0.32 EPS for the quarter, topping the consensus estimate of $0.27 by $0.05. Kenvue had a return on equity of 20.81% and a net margin of 10.61%.The firm had revenue of $3.91 billion during the quarter, compared to analysts’ expectations of $3.84 billion. During the same period last year, the business earned $0.24 earnings per share. Kenvue’s quarterly revenue was up 4.5% compared to the same quarter last year. Sell-side analysts forecast that Kenvue Inc. will post 1.16 EPS for the current year.

Kenvue Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, May 27th. Investors of record on Wednesday, May 13th were given a $0.2075 dividend. This represents a $0.83 annualized dividend and a yield of 4.6%. The ex-dividend date of this dividend was Wednesday, May 13th. Kenvue’s dividend payout ratio is 97.65%.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.